Provided by Tiger Fintech (Singapore) Pte. Ltd.

Dianthus Therapeutics Inc.

35.61
+0.03500.10%
Volume:1.38M
Turnover:49.05M
Market Cap:1.15B
PE:-10.96
High:36.99
Open:33.80
Low:33.50
Close:35.57
52wk High:36.99
52wk Low:13.37
Shares:32.19M
Float Shares:13.46M
Volume Ratio:2.17
T/O Rate:10.28%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.2490
EPS(LYR):-2.5506
ROE:-34.71%
ROA:-23.37%
PB:3.78
PE(LYR):-13.96

Loading ...

Sep 09, 2025

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Sep 08, 2025

Major Issues Report

Form 8-K - Current report
Aug 07, 2025

Quarterly Report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Aug 07, 2025

Major Issues Report

Form 8-K - Current report
May 22, 2025

Major Issues Report

Form 8-K - Current report
May 13, 2025

Quarterly Report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
May 13, 2025

Major Issues Report

Form 8-K - Current report
Mar 11, 2025

Annual Report

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
Mar 11, 2025

Employee Stock Ownership

Form S-8 - Securities to be offered to employees in employee benefit plans
Mar 11, 2025

Major Issues Report

Form 8-K - Current report
Mar 05, 2025

Major Issues Report

Form 8-K - Current report
Dec 12, 2024

Major Issues Report

Form 8-K - Current report
Dec 03, 2024

Beneficial Ownership Change

Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
Nov 22, 2024

Beneficial Ownership Change

Form SC 13G - Statement of Beneficial Ownership by Certain Investors
Nov 14, 2024

Beneficial Ownership Change

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
Nov 14, 2024

Beneficial Ownership Change

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
Nov 08, 2024

Quarterly Report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Nov 07, 2024

Major Issues Report

Form 8-K - Current report
Oct 11, 2024

Beneficial Ownership Change

Form SC 13G - Statement of Beneficial Ownership by Certain Investors
Oct 07, 2024

Correspondence

Form CORRESP - Correspondence